Haemonetics (HAE) return on invested capital (ROIC)

Return on invested capital · fiscal 2026
10.3%

Haemonetics (HAE) earned a return on invested capital of 10.3% in fiscal 2026 (the year ended March 31, 2026). That is 1.2 percentage points higher than the 9.1% of fiscal 2025. Figures as of 18 Nov 2026, 01:02 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2026
10.3%
Change on fiscal 2025
+1.2 pts
Highest on record
10.3%fiscal 2026
Lowest on record
8.5%fiscal 2024
Fiscal years on record
42023–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Haemonetics return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2023–2026), the highest was 10.3% in fiscal 2026 and the lowest 8.5% in fiscal 2024. The fiscal 2026 figure is higher than in every one of the 3 earlier fiscal years on record, whose median is 9.1%.

History · 4 fiscal years

Return on invested capital by fiscal year

Haemonetics return on invested capital (ROIC), year by year

Haemonetics (HAE) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
202610.3% 1.2 pts up
20259.1% 0.6 pts up
20248.5% 1.2 pts down
20239.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Haemonetics and comparable companies
CompanyReturn on invested capitalFiscal year
Hims & Hers Health HIMS9.7%2025
PTC Therapeutics PTCT150.9%2025
Haemonetics HAE10.3%2026
Erasca ERAS-107.9%2025
Concentra Group Holdings Parent CON10.7%2025
Merit Medical Systems MMSI7.1%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HAE

Haemonetics, figure by figure

Haemonetics (HAE) overview: price, valuation and scorecardAll health care companies by market value

Haemonetics return on invested capital (ROIC): questions and answers

What is Haemonetics's return on invested capital?

Haemonetics (HAE) earned a return on invested capital of 10.3% in fiscal 2026 (the year ended March 31, 2026). That is 1.2 percentage points higher than the 9.1% of fiscal 2025.

Is Haemonetics's return on invested capital high or low compared with its own history?

The fiscal 2026 figure is higher than in every one of the 3 earlier fiscal years on record, whose median is 9.1%.

What are the highest and lowest return on invested capital figures on record for Haemonetics?

Across the 4 fiscal years on record (2023–2026), the highest was 10.3% in fiscal 2026 and the lowest 8.5% in fiscal 2024.

How is Haemonetics's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Haemonetics (HAE) return on invested capital (ROIC)”, data as of 18 November 2026. https://funkfolio.com/stock/HAE/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.